FDA approves Cubists' drug for antibiotic-resistant bacteria

December 19, 2014 11:12 PM

15 0

(Reuters) - Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs.

The drug, Zerbaxa, treats infections caused by gram-negative bacteria — a type of antibiotic-resistant pathogens, often called superbugs.

Read more

To category page